Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
IPO Year:
Exchange: NASDAQ
Website: rainthera.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2023 | Buy → Neutral | ROTH MKM | |
| 3/21/2023 | $11.00 | Outperform | SVB Securities |
| 1/31/2023 | $21.00 | Buy | ROTH Capital |
| 1/23/2023 | $18.00 | Buy | Mizuho |
| 9/12/2022 | $10.00 | Buy | H.C. Wainwright |
| 4/1/2022 | $15.00 | Outperform | Oppenheimer |
| 9/14/2021 | $22.00 | Neutral | Goldman |
| 7/20/2021 | $25.00 | Overweight | Piper Sandler |
Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. ("Pathos") today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. ("Merger Sub"), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (NASDAQ:RAIN) ("Rain") for $1.16 per share in cash plus one contingent value right per share (each, a "CVR"), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated as of January 26, 2024, by and among Pathos, Merger Sub, Equiniti Trust Company, LLC, and Forti
NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) ("Rain"), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. ("Pathos") will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a "CVR") for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions contemplated by the Merger Agreement (collectively, the "Transaction"). The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023. The Rain Board reached this determinati
NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company's key developments and business operations. "Rain continues to evaluate a number of strategic opportunities to add value for its stockholders," said Avanish Vellanki, co-founder and chief executive officer of Rain. "We anticipate being able to provide a public update on our efforts before the end of the year." Third Quarter 2023 Financial Highlights For the three and nine months ended September 30, 2023, Rain reported a net loss of $7.0 million and $49.6 million, respect
NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NASDAQ:RAIN) ("Rain") confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right ("CVR") representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain's programs. Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are committed to acting in the best interests of all stockholders. Consistent with its fiduciary duties, Rain's Board of Directors, i
– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca
– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma (DD LPS) are ongoing with data and findings to be presented at a medical conference in 4Q23 – – Company continuing to evaluate opportunities for expansion of its pipeline across precision oncology strategies – – Overall workforce reduction of approximately 65% of the Company's employees; with a transition of Chief Medical Officer (CMO) responsibilities – – Year-end 2023 cash guidance of $75-80mm, with cash runway to year-e
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p
– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Required number of progression events achieved in the Phase 3 pivotal MANTRA trial to trigger the primary analysis of progression free survival (PFS) in patients with dedifferentiated liposarcoma (DDLPS) – – Topline data for the MANTRA trial expected this quarter – – Phase 2 MANTRA-2 trial continues to enroll across MDM2-amplified advanced solid tumor types – – Phase 1/2 MANTRA-4 trial in advanced solid tumors exhibiting loss of the
Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.
– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p
– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Required number of progression events achieved in the Phase 3 pivotal MANTRA trial to trigger the primary analysis of progression free survival (PFS) in patients with dedifferentiated liposarcoma (DDLPS) – – Topline data for the MANTRA trial expected this quarter – – Phase 2 MANTRA-2 trial continues to enroll across MDM2-amplified advanced solid tumor types – – Phase 1/2 MANTRA-4 trial in advanced solid tumors exhibiting loss of the
NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the first quarter ended March 31, 2023 and highlights of recent progress on Thursday, May 11, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: May 11, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers
– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Topline data for Phase 3 pivotal MANTRA trial expected in second quarter of 2023 – – Phase 2 MANTRA-2 trial continues to enroll – – Phase 1/2 MANTRA-4 trial anticipated to commence in mid-2023 – – Management to host conference call and webcast today at 5:00 PM Eastern Time – NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage biotechnology company developing precision oncology t
NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: March 9, 2023Time: 2:00 PT (5:00 p
– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 – – Phase 3 pivotal MANTRA trial topline data now anticipated in first quarter of 2023 – – Phase 2 MANTRA-2 trial preliminary interim data demonstrates encouraging monotherapy signal in ten evaluable patients; MANTRA-2 continues to enroll – – Phase 2 MANTRA-3 trial deprioritized to rationalize use of financial resources – – Phase 1/2 MANTRA-4 trial anticipated to commence in first quarter 2023 – – Management to host conference call and webcast today at 5:00 PM Eastern Time – NEWARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Rain Ther
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: November 10, 2022Time: 2:00 PT (5:00 pm ET)D
– Quarter-end cash position of $105.7 million provides ample cash runway into mid-2024 – – Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance; topline data anticipated in first half of 2023 – – Phase 2 MANTRA-2 trial ongoing as planned with interim data anticipated in fourth quarter 2022 – – Management to host conference call and webcast today at 5:00 PM Eastern Time – NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ:RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactiva
ROTH MKM downgraded Rain Oncology from Buy to Neutral
SVB Securities initiated coverage of Rain Oncology with a rating of Outperform and set a new price target of $11.00
ROTH Capital resumed coverage of Rain Oncology with a rating of Buy and set a new price target of $21.00
Mizuho initiated coverage of Rain Oncology with a rating of Buy and set a new price target of $18.00
H.C. Wainwright initiated coverage of Rain Therapeutics with a rating of Buy and set a new price target of $10.00
Oppenheimer initiated coverage of Rain Therapeutics with a rating of Outperform and set a new price target of $15.00
Goldman resumed coverage of Rain Therapeutics with a rating of Neutral and set a new price target of $22.00
Piper Sandler initiated coverage of Rain Therapeutics with a rating of Overweight and set a new price target of $25.00
Guggenheim initiated coverage of Rain Therapeutics with a rating of Buy and set a new price target of $26.00
Piper Sandler initiated coverage of Rain Therapeutics with a rating of Overweight and set a new price target of $25.00
3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
424B3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
10-Q - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
SCHEDULE 13G - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Subject)
EFFECT - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
424B3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
POS AM - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
10-K - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
8-K - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
NT 10-K - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
424B3 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Filer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Enhancement Technologies Holdco, Inc. (0002028293) (Issuer)
4 - Rain Oncology Inc. (0001724979) (Issuer)
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)
SC 13G - Rain Oncology Inc. (0001724979) (Subject)
SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)